Similar articles

• Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.

  Zhan Y, Yang Z, Li L, Ye D, Wu H, Fu R, Zhao S, Wang Y, Zhou R, Chen R. Zhan Y, et al. Jpn J Infect Dis. 2011;64(3):190-4. Jpn J Infect Dis. 2011. PMID: 21617301
• Effectiveness and safety of pandemic influenza A (H1N1) 2009 vaccine in healthcare workers at a university hospital in Japan.

  Igari H, Watanabe A, Chiba H, Shoji K, Segawa S, Nakamura Y, Watanabe M, Suzuki K, Sato T. Igari H, et al. Jpn J Infect Dis. 2011;64(3):177-82. Jpn J Infect Dis. 2011. PMID: 21617299
• Head-to-head comparison of pandemic influenza vaccines.

  Leroux-Roels G, Leroux-Roels I. Leroux-Roels G, et al. Lancet Infect Dis. 2011 Feb;11(2):74-5. doi: 10.1016/S1473-3099(10)70298-X. Epub 2010 Dec 16. Lancet Infect Dis. 2011. PMID: 21168368 No abstract available.
• Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

  Walker WT, Faust SN. Walker WT, et al. Expert Rev Vaccines. 2010 Dec;9(12):1385-98. doi: 10.1586/erv.10.141. Expert Rev Vaccines. 2010. PMID: 21105775 Review.
• Panvax(®): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009.

  McVernon J, Nolan T. McVernon J, et al. Expert Rev Vaccines. 2011 Jan;10(1):35-43. doi: 10.1586/erv.10.143. Expert Rev Vaccines. 2011. PMID: 21162618 Review.